Ainos(US:AIMD)2025-11-13 21:16Revenue Performance - Ainos reported revenues of $2,167 in Q3 2025, a significant increase from nil in Q3 2024, attributed to sales of VELDONA pet supplements and pilot programs for the AI Nose platform [128][129]. - The company's revenue for the first nine months of 2025 was $113,037, a 445% increase from $20,729 in the same period of 2024 [140]. Gross Profit and Loss - Gross profit for Q3 2025 was $1,690, compared to a gross loss of $547 in Q3 2024, driven by increased sales volume [130]. - Gross profit for the first nine months of 2025 was $93,390, compared to a gross loss of $31,945 in the first nine months of 2024, reflecting a $125,335 improvement [143]. Expenses - Research and development (R&D) expenses were $1,990,630 in Q3 2025, a slight decrease of 2% from $2,022,244 in Q3 2024, due to reduced co-research expenses [131]. - Research and development expenses decreased by $459,134 (8%) to $5,626,514 in the first nine months of 2025 from $6,085,648 in the first nine months of 2024 [144]. - Selling, general and administrative (SG&A) expenses decreased by 22% to $795,253 in Q3 2025 from $1,015,758 in Q3 2024, primarily due to lower share-based compensation and reduced fees [134]. - Selling, general and administrative expenses increased by $1,069,571 (35%) to $4,159,627 in the first nine months of 2025 compared to $3,090,056 in the first nine months of 2024 [146]. Operating and Net Loss - Operating loss for the first nine months of 2025 was $9,692,751, a 5% increase from $9,207,649 in the first nine months of 2024 [148]. - Net loss for the first nine months of 2025 was $10,302,714, representing a 1% increase from $10,209,149 in the same period of 2024 [150]. Cash Position - As of September 30, 2025, Ainos had cash and cash equivalents of $1,128,217, with plans to fund operations through business revenues and external financing [123]. - Available cash as of September 30, 2025, was $1,128,217, down from $3,892,919 as of December 31, 2024 [151]. - Cash used in operating activities decreased by $1,184,357 to $3,759,679 in the first nine months of 2025 compared to $4,944,036 in the first nine months of 2024 [153]. Future Plans and Developments - Ainos plans to enter commercial pilot phase for the AI Nose platform across industrial, robotics, and long-term care environments in the second half of 2025 [107]. - The HIV oral wart program under the VELDONA platform has received Orphan Drug Designation from the U.S. FDA, with clinical trials planned in Taiwan [117]. - Ainos signed a three-year subscription-based order valued at $2.1 million with ASE Technology Holding Co., Ltd. for deploying 1,400 AI Nose units across three manufacturing sites [111]. - The company anticipates funding operations over the next twelve months through cash reserves, business revenues, and potential debt financing [155]. Other Notable Changes - Ainos has ceased selling COVID-19 antigen test kits as of Q1 2024, focusing on advancing its AI Nose and VELDONA platforms [119]. - Interest expense for the first nine months of 2025 was $534,986, an increase of 24% from $432,097 in the same period of 2024 [149].